So far, clinical treatment of AD therapeutics has been dominated by the use of western medicine, that is to say, acetylcholinesterase (AChE) inhibitors, NMDA receptor (NMDAR) antagonists, amyloid production or secretion inhibitors, and inflammation inhibitors (Orlov, 2019). The gene discussed is ACHE; the disease is Alzheimer disease.